257 related articles for article (PubMed ID: 33485369)
21. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
23. Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
Karita E; Nyombayire J; Ingabire R; Mazzei A; Sharkey T; Mukamuyango J; Allen S; Tichacek A; Parker R; Priddy F; Sayinzoga F; Nsanzimana S; Robinson C; Katwere M; Anumendem D; Leyssen M; Schaefer M; Wall KM
Trials; 2022 Jun; 23(1):513. PubMed ID: 35725488
[TBL] [Abstract][Full Text] [Related]
24. Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.
Barry H; Lhomme E; Surénaud M; Nouctara M; Robinson C; Bockstal V; Valea I; Somda S; Tinto H; Meda N; Greenwood B; Thiébaut R; Lacabaratz C
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011500. PubMed ID: 38603720
[TBL] [Abstract][Full Text] [Related]
25. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
[TBL] [Abstract][Full Text] [Related]
26. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
[TBL] [Abstract][Full Text] [Related]
27. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
Halperin SA; Arribas JR; Rupp R; Andrews CP; Chu L; Das R; Simon JK; Onorato MT; Liu K; Martin J; Helmond FA;
J Infect Dis; 2017 Jun; 215(12):1789-1798. PubMed ID: 28549145
[TBL] [Abstract][Full Text] [Related]
28. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.
Vianello E; Gonzalez-Dias P; van Veen S; Engele CG; Quinten E; Monath TP; Medaglini D; ; ; Santoro F; Huttner A; Dubey S; Eichberg M; Ndungu FM; Kremsner PG; Essone PN; Agnandji ST; Siegrist CA; Nakaya HI; Ottenhoff THM; Haks MC
Lancet Microbe; 2022 Feb; 3(2):e113-e123. PubMed ID: 35544042
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Simon JK; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BG; Welebob C; Hanson ME; Grais RF
Vaccine; 2022 Nov; 40(46):6599-6606. PubMed ID: 36208978
[TBL] [Abstract][Full Text] [Related]
30. PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.
Bolay FK; Grandits G; Lane HC; Kennedy SB; Johnson MP; Fallah MP; Wilson B; Njoh WS; McNay LA; Hensley LE; Higgs ES
J Infect Dis; 2019 Apr; 219(10):1634-1641. PubMed ID: 30561672
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.
Kennedy SB; Bolay F; Kieh M; Grandits G; Badio M; Ballou R; Eckes R; Feinberg M; Follmann D; Grund B; Gupta S; Hensley L; Higgs E; Janosko K; Johnson M; Kateh F; Logue J; Marchand J; Monath T; Nason M; Nyenswah T; Roman F; Stavale E; Wolfson J; Neaton JD; Lane HC;
N Engl J Med; 2017 Oct; 377(15):1438-1447. PubMed ID: 29020589
[TBL] [Abstract][Full Text] [Related]
32. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
[TBL] [Abstract][Full Text] [Related]
33. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Bockstal V; Shukarev G; McLean C; Goldstein N; Bart S; Gaddah A; Anumenden D; Stoop JN; Marit de Groot A; Pau MG; Hendriks J; De Rosa SC; Cohen KW; McElrath MJ; Callendret B; Luhn K; Douoguih M; Robinson C
PLoS One; 2022; 17(10):e0274906. PubMed ID: 36197845
[TBL] [Abstract][Full Text] [Related]
34. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.
Regules JA; Beigel JH; Paolino KM; Voell J; Castellano AR; Hu Z; Muñoz P; Moon JE; Ruck RC; Bennett JW; Twomey PS; Gutiérrez RL; Remich SA; Hack HR; Wisniewski ML; Josleyn MD; Kwilas SA; Van Deusen N; Mbaya OT; Zhou Y; Stanley DA; Jing W; Smith KS; Shi M; Ledgerwood JE; Graham BS; Sullivan NJ; Jagodzinski LL; Peel SA; Alimonti JB; Hooper JW; Silvera PM; Martin BK; Monath TP; Ramsey WJ; Link CJ; Lane HC; Michael NL; Davey RT; Thomas SJ;
N Engl J Med; 2017 Jan; 376(4):330-341. PubMed ID: 25830322
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
[TBL] [Abstract][Full Text] [Related]
37. Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
Watson-Jones D; Kavunga-Membo H; Grais RF; Ahuka S; Roberts N; Edmunds WJ; Choi EM; Roberts CH; Edwards T; Camacho A; Lees S; Leyssen M; Spiessens B; Luhn K; Douoguih M; Hatchett R; Bausch DG; Muyembe JJ;
BMJ Open; 2022 Mar; 12(3):e055596. PubMed ID: 35260458
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
39. Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.
Kitonsa J; Ggayi AB; Anywaine Z; Kisaakye E; Nsangi L; Basajja V; Nyantaro M; Watson-Jones D; Shukarev G; Ilsbroux I; Robinson C; Kaleebu P
Glob Health Action; 2020 Dec; 13(1):1829829. PubMed ID: 33073737
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
